This paper is in the following e-collection/theme issue:

Non-Randomized Studies (funded, non-eHealth) (143)

Published on in Vol 5, No 3 (2016): Jul-Sept

EXpanding Treatment for Existing Neurological Disease (EXTEND): An Open-Label Phase II Clinical Trial of Hydroxyurea Treatment in Sickle Cell Anemia

EXpanding Treatment for Existing Neurological Disease (EXTEND): An Open-Label Phase II Clinical Trial of Hydroxyurea Treatment in Sickle Cell Anemia

EXpanding Treatment for Existing Neurological Disease (EXTEND): An Open-Label Phase II Clinical Trial of Hydroxyurea Treatment in Sickle Cell Anemia

Authors of this article:

Angela E Rankine-Mullings1 Author Orcid Image ;   Courtney R Little2 Author Orcid Image ;   Marvin E Reid3 Author Orcid Image ;   Deanne P Soares3 Author Orcid Image ;   Carolyn Taylor-Bryan3 Author Orcid Image ;   Jennifer M Knight-Madden1 Author Orcid Image ;   Susan E Stuber2 Author Orcid Image ;   Asha V Badaloo3 Author Orcid Image ;   Karen Aldred1 Author Orcid Image ;   Margaret E Wisdom-Phipps1 Author Orcid Image ;   Teresa Latham2 Author Orcid Image ;   Russell E Ware2 Author Orcid Image
Article Authors Cited by (9) Tweetations (1) Metrics

Journals

  1. Case M, Shirinpour S, Vijayakumar V, Zhang H, Datta Y, Nelson S, Pergami P, Darbari D, Gupta K, He B. Graph theory analysis reveals how sickle cell disease impacts neural networks of patients with more severe disease. NeuroImage: Clinical 2019;21:101599 View
  2. Estcourt L, Kohli R, Hopewell S, Trivella M, Wang W. Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease. Cochrane Database of Systematic Reviews 2020;2020(7) View
  3. Brewin J, Kaya B, Chakravorty S. How I manage sickle cell patients with high transcranial doppler results. British Journal of Haematology 2017;179(3):377 View
  4. Smart L, Hernandez A, Ware R. Sickle cell disease: Translating clinical care to low-resource countries through international research collaborations. Seminars in Hematology 2018;55(2):102 View
  5. Li B, Geng S, Dai Y. Therapeutic effect of vascular interventional therapy and aspirin combined with defibrase on cerebral ischemia in rats. Experimental and Therapeutic Medicine 2018 View
  6. Jeste N, Sánchez L, Urcuyo G, Bergés M, Luden J, Stuber S, Latham T, Mena R, Nieves R, Ware R. Stroke Avoidance for Children in REpública Dominicana (SACRED): Protocol for a Prospective Study of Stroke Risk and Hydroxyurea Treatment in Sickle Cell Anemia. JMIR Research Protocols 2017;6(6):e107 View
  7. Power-Hays A, Ware R. Effective use of hydroxyurea for sickle cell anemia in low-resource countries. Current Opinion in Hematology 2020;27(3):172 View
  8. Marks L, Munube D, Kasirye P, Mupere E, Jin Z, LaRussa P, Idro R, Green N. Stroke Prevalence in Children With Sickle Cell Disease in Sub-Saharan Africa: A Systematic Review and Meta-Analysis. Global Pediatric Health 2018;5 View
  9. Rankine‐Mullings A, Reid M, Soares D, Taylor‐Bryan C, Wisdom‐Phipps M, Aldred K, Latham T, Schultz W, Knight‐Madden J, Badaloo A, Lane A, Adams R, Ware R. Hydroxycarbamide treatment reduces transcranial Doppler velocity in the absence of transfusion support in children with sickle cell anaemia, elevated transcranial Doppler velocity, and cerebral vasculopathy: the EXTEND trial. British Journal of Haematology 2021;195(4):612 View